Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply” and “GSK insider trading Form 4 transactions.”
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK plc reports purchases of its ordinary shares under its ongoing buyback programme. On 28 August 2025 the company, acting through broker Merrill Lynch International, acquired 236,167 ordinary shares of 31.25 pence each with a reported lowest price of 1,460.50p, highest price of 1,479.00p and an average/aggregate price shown as 1,466.11p. The purchased shares will be held as treasury shares and the announcement confirms this forms part of the non-discretionary agreement with the broker entered into on 4 June 2025. Since that agreement the Company has purchased 26,021,500 ordinary shares. After the 28 August purchase GSK will hold 244,155,883 shares in treasury and have 4,071,236,744 ordinary shares in issue (excluding treasury), giving a total number of voting rights of 4,071,236,744 and treasury shares representing 6.00% of voting rights. Detailed trade-level execution data across the London Stock Exchange and CBOE Europe are included.
GSK plc purchased 260,986 ordinary shares on 27 August 2025 through Merrill Lynch International as part of its existing buyback programme. The trades were executed on the London Stock Exchange (and reported across recognised venues) at prices between 1,471.00p and 1,484.00p, with an aggregated average price reported as 1,477.76p. Since the non-discretionary broker agreement of 4 June 2025, the Company has bought 25,785,333 ordinary shares. After this transaction GSK will hold 243,919,716 shares in treasury and will have 4,071,472,911 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,071,472,911, and treasury shares represent 5.99% of voting rights.
GSK plc reports that, acting through Merrill Lynch International, it purchased 251,452 ordinary shares of 31.75p each on 26 August 2025 under its ongoing buyback programme. Since the non-discretionary agreement dated 4 June 2025, the Company has purchased a total of 25,524,347 ordinary shares. Following the latest purchase the Company will hold 243,658,730 ordinary shares in treasury and have 4,071,733,897 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,071,733,897, and the percentage of voting rights attributable to treasury shares is reported as 5.98%.
GSK plc reports on 22 August 2025 that, acting through its corporate broker Merrill Lynch International under a non-discretionary agreement entered into on 4 June 2025, it purchased 243,639 ordinary shares for holding as Treasury shares as part of its existing buyback programme. Since 4 June 2025 the company has purchased a total of 25,272,895 ordinary shares. After this purchase GSK will hold 243,407,278 ordinary shares in treasury and have 4,071,985,349 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,071,985,349 and the percentage of voting rights attributable to ordinary shares held in treasury is 5.98%.
GSK plc reported a share purchase under its ongoing buyback programme. On 21 August 2025 the Company, acting through Merrill Lynch International, bought 238,918 ordinary shares of 31.75 pence each at prices between 1,473.00p and 1,492.00p, with individual trades listed at execution prices around 1,474p–1,486p. These shares will be held as Treasury shares.
Since the non-discretionary broker agreement dated 4 June 2025, GSK has purchased 25,029,256 ordinary shares. After the 21 August purchase the Company holds 243,163,639 ordinary shares in treasury and has 4,072,228,095 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,072,228,095 and the percentage of voting rights attributable to ordinary shares held in treasury is 5.97%.
GSK plc reports that, acting through Merrill Lynch International, it purchased 214,694 ordinary shares of 31.25p each on 20 August 2025 as part of its ongoing buyback programme under the non-discretionary broker agreement dated 4 June 2025. Since 4 June 2025 the Company has purchased 24,790,338 ordinary shares. The purchased shares will be held as Treasury shares bringing the total held in treasury to 242,924,721. The Company has 4,072,467,013 ordinary shares in issue excluding Treasury shares and the total number of voting rights is 4,072,467,013. The percentage of voting rights attributable to treasury shares is 5.97%.
GSK plc reported a purchase of 211,358 ordinary shares of 31.75p each on 19 August 2025 under its announced buyback programme executed by Merrill Lynch International. The shares will be held as treasury stock. Since the non-discretionary broker agreement dated 4 June 2025, the Company has bought 24,575,644 ordinary shares. After this transaction GSK will hold 242,710,027 shares in treasury and will have 4,072,681,707 ordinary shares in issue (excluding treasury), giving a total voting rights denominator of 4,072,681,707 and treasury shares representing 5.96% of voting rights. The filing lists detailed trade-by-trade prices and venues for the aggregated purchases.
GSK plc reported a transaction in its ordinary shares on 18 August 2025 under its ongoing buyback programme. Acting through Merrill Lynch International, the Company purchased 221,293 ordinary shares at prices shown in the schedule, with an average price reported as 1,437.72p. The purchased shares will be held as Treasury shares.
Since entering the non-discretionary broker agreement on 4 June 2025, GSK has bought 24,364,286 ordinary shares. After this trade GSK will hold 242,498,669 shares in treasury and will have 4,072,893,065 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,072,893,065 and treasury shares represent 5.95% of voting rights.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
